Cargando…

MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy

The treatment of hypercholesterolemia is mainly based on statins. However, the response to pharmacological therapy shows high inter-individual variability, resulting in variable effects in both lipid lowering and risk reduction. Thus, a better understanding of the lipid-lowering mechanisms and respo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saavedra, Kathleen, Leal, Karla, Saavedra, Nicolás, Prado, Yalena, Paez, Isis, Ubilla, Carmen G., Rojas, Gabriel, Salazar, Luis A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104095/ https://www.ncbi.nlm.nih.gov/pubmed/35563413 http://dx.doi.org/10.3390/ijms23095022

Ejemplares similares

MicroRNA-33b is a Potential Non-Invasive Biomarker for Response to Atorvastatin Treatment in Chilean Subjects With Hypercholesterolemia: A Pilot Study
por: Ubilla, Carmen Gloria, et al.
Publicado: (2021)

Atorvastatin Increases the Expression of Long Non-Coding RNAs ARSR and CHROME in Hypercholesterolemic Patients: A Pilot Study
por: Paez, Isis, et al.
Publicado: (2020)

Cholesterol-Related lncRNAs as Response Predictors of Atorvastatin Treatment in Chilean Hypercholesterolemic Patients: A Pilot Study
por: Paez, Isis, et al.
Publicado: (2023)

SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals
por: Prado, Yalena, et al.
Publicado: (2015)

MicroRNAs Involved in Intrinsic Apoptotic Pathway during Cisplatin-Induced Nephrotoxicity: Potential Use of Natural Products against DDP-Induced Apoptosis
por: Loren, Pía, et al.
Publicado: (2022)

MicroRNAs hsa-miR-618 and hsa-miR-297 Might Modulate the Pleiotropic Effects Exerted by Statins in Endothelial Cells Through the Inhibition of ROCK2 Kinase: in-silico Approach
por: Leal, Karla, et al.
Publicado: (2021)

CYP2C19(⁎)2 Polymorphism in Chilean Patients with In-Stent Restenosis Development and Controls
por: Ruedlinger, Jenny, et al.
Publicado: (2017)

Cholesteryl Ester Transfer Protein Gene and Effectiveness of Lipid Lowering of Atorvastatin
por: Kolovou, Genovefa, et al.
Publicado: (2010)

Modulation of the Cardiovascular Effects of Polycyclic Aromatic Hydrocarbons: Physical Exercise as a Protective Strategy
por: Rojas, Gabriel A., et al.
Publicado: (2023)

Efficacy and safety of Zhibitai in combination with atorvastatin for lipid lowering in patients with coronary heart disease
por: Xu, Danyan, et al.
Publicado: (2017)

Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects
por: Woo, Hye In, et al.
Publicado: (2017)

Polycyclic Aromatic Hydrocarbons (PAHs) Exposure Triggers Inflammation and Endothelial Dysfunction in BALB/c Mice: A Pilot Study
por: Rojas, Gabriel A., et al.
Publicado: (2022)

Contribution of MicroRNAs in Chemoresistance to Cisplatin in the Top Five Deadliest Cancer: An Updated Review
por: Loren, Pía, et al.
Publicado: (2022)

Characterization of microbial communities from gut microbiota of hypercholesterolemic and control subjects
por: Morales, Cristian, et al.
Publicado: (2022)

Vitamin D Levels and Lipid Response to Atorvastatin
por: Pérez-Castrillón, José Luis, et al.
Publicado: (2010)

Atorvastatin downregulates HSP22 expression in an atherosclerotic model in vitro and in vivo
por: Chen, Qi, et al.
Publicado: (2019)

Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study
por: Berne, Christian, et al.
Publicado: (2005)

Cultural Care Practices Provided at Home by the Zenú Indigenous Mothers to their Premature Children and to Those with Low Birth Weight
por: Ortiz Anaya, Yalena, et al.
Publicado: (2022)

Imaging of Intracellular and Extracellular ROS Levels in Atherosclerotic Mouse Aortas Ex Vivo: Effects of Lipid Lowering by Diet or Atorvastatin
por: Ekstrand, Matias, et al.
Publicado: (2015)

Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse
por: Ai, Cong, et al.
Publicado: (2018)

Histological Evaluation and Gene Expression Profiling of Autophagy-Related Genes for Cartilage of Young and Senescent Rats
por: Arias, Consuelo, et al.
Publicado: (2020)

Atorvastatin Attenuates Metabolic Remodeling in Ischemic Myocardium through the Downregulation of UCP2 Expression
por: Yang, Chunyan, et al.
Publicado: (2018)

Atorvastatin Downregulates In Vitro Methyl Methanesulfonate and Cyclophosphamide Alkylation-Mediated Cellular and DNA Injuries
por: Araujo-Lima, Carlos F., et al.
Publicado: (2018)

Use of Atorvastatin in Lipid Disorders and Cardiovascular Disease in Chinese Patients
por: Ye, Yi-Cong, et al.
Publicado: (2015)

Impact of the Gut Microbiota on Atorvastatin Mediated Effects on Blood Lipids
por: Zimmermann, Friederike, et al.
Publicado: (2020)

Atorvastatin and sildenafil lower blood pressure and improve endothelial dysfunction, but only atorvastatin increases vascular stores of nitric oxide in hypertension()
por: Guimarães, Danielle A., et al.
Publicado: (2013)

Association between the TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy
por: Zhang, Qing-Hui, et al.
Publicado: (2018)

Dysregulated MicroRNAs as Biomarkers or Therapeutic Targets in Cisplatin-Induced Nephrotoxicity: A Systematic Review
por: de Godoy Torso, Nadine, et al.
Publicado: (2021)

Renoprotective Effects of Atorvastatin in Diabetic Mice: Downregulation of RhoA and Upregulation of Akt/GSK3
por: Bruder-Nascimento, Thiago, et al.
Publicado: (2016)

Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling
por: Okoye, Isobel, et al.
Publicado: (2017)

Atorvastatin potentiates the chemosensitivity of human liver cancer cells to cisplatin via downregulating YAP1
por: Guo, Liwen, et al.
Publicado: (2021)

Circulating miRNA-23b and miRNA-143 Are Potential Biomarkers for In-Stent Restenosis
por: Saavedra, Nicolás, et al.
Publicado: (2020)

Comparative Study of Ezetimibe and Atorvastatin Alone and in Combination on Lipid Profile in Rats
por: Prasad, Anju, et al.
Publicado: (2013)

Atorvastatin Restores PPARα Inhibition of Lipid Metabolism Disorders by Downregulating miR-21 Expression to Improve Mitochondrial Function and Alleviate Diabetic Nephropathy Progression
por: Xiang, Jiayi, et al.
Publicado: (2022)

Atorvastatin attenuates plaque vulnerability by downregulation of EMMPRIN expression via COX-2/PGE2 pathway
por: Liang, Xing, et al.
Publicado: (2017)

Comparison of Low-Dose Rosuvastatin with Atorvastatin in Lipid-Lowering Efficacy and Safety in a High-Risk Pakistani Cohort: An Open-Label Randomized Trial
por: Arshad, Abdul Rehman
Publicado: (2014)

ANGPTL4 variants and their haplotypes are associated with serum lipid levels, the risk of coronary artery disease and ischemic stroke and atorvastatin cholesterol-lowering responses
por: Yang, Qian, et al.
Publicado: (2018)

Comprehensive Study of Atorvastatin Nanostructured Lipid Carriers through Multivariate Conceptualization and Optimization
por: Ghanem, Heba A., et al.
Publicado: (2021)

Hypolipidemic Activity of Olive Oil-Based Nanostructured Lipid Carrier Containing Atorvastatin
por: Elsewedy, Heba S., et al.
Publicado: (2022)

Epigenetic Modifications of Major Depressive Disorder
por: Saavedra, Kathleen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ceua53khmu550fe0g88uh50ld2